The poster presentation: “A phase 1/2 clinical trial of antiVISTA – KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors” was presented by Dr. Jason Henry, M.D., ...
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
Posters will be made available on the Kineta website following presentations at the conference. KEYTRUDA ® is a registered trademark ... and a preclinical monoclonal antibody targeting CD27. For more ...
Bristol Myers Squibb today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFYtm (xanomeline and trospium chloride) ...
NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...
See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information. Selected Important Safety Information for KEYTRUDA Severe and Fatal Immune-Mediated Adverse ...
TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line ...
Released on Deol's birthday, the first-look poster showcases him in a fierce avatar. Scheduled for a potential Republic Day 2025 release, 'Jaat' might clash with Akshay Kumar's 'Sky Force.' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback